Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | PHGDH | O43175 | 1/20 | 0.64 |
| ▸ | MGLL | Q99685 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL8379754 | 0.96 | ALDH1A1 (0.60) | ALDH1A1HSD17B10HPGDPOLBPHGDH | |
| SCHEMBL11070729 | 0.93 | KMT2A (0.59) | ALDH1A1HSD17B10HPGDPOLBPHGDH | |
| SCHEMBL24120195 | 0.90 | HPGD (0.61) | ALDH1A1HSD17B10HPGDPOLBPHGDH | |
| SCHEMBL11068661 | 0.89 | ALDH1A1 (0.64) | ALDH1A1HSD17B10HPGDPOLBPHGDH | |
| SCHEMBL9585721 | 0.86 | POLB (0.81) | ALDH1A1HSD17B10HPGDPOLBPHGDH | |
| SCHEMBL10722382 | 0.86 | POLB (0.81) | ALDH1A1HSD17B10HPGDPOLBPHGDH | |
| SCHEMBL7824233 | 0.84 | ALDH1A1 (0.62) | ALDH1A1HSD17B10HPGDPOLBPHGDH | |
| SCHEMBL27811868 | 0.83 | HPGD (0.53) | ALDH1A1HSD17B10HPGDMGLLMAPT | |
| SCHEMBL2987838 | 0.83 | MTHFD2 (0.54) | ALDH1A1HPGDKMT2ACA12CA1 | |
| SCHEMBL4251742 | 0.82 | KMT2A (0.77) | ALDH1A1HSD17B10HPGDPOLBPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996577-B1 | HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | MERCK SHARP & DOHME (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2041117-B1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | MERCK SHARP & DOHME (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120157466-A1 | HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | MERCK SHARP & DOHME CORP. | 2012-06-21 | — | — | US | disclosed |
| US-20120157466-A1 | HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | MERCK SHARP & DOHME CORP. | 2012-06-21 | — | — | US | disclosed |
| US-8017616-B2 | Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| US-7951815-B2 | Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-7902199-B2 | Chemokine receptor CXCR3; inflammatory conditions (psoriasis and inflammatory bowel disease), autoimmune diseases, graft rejection, infectious diseases, cancers and tumors, type I diabetes, viral meningitis and tuberculoid leprosy; 1-(pyrid-3-yl)-4-(piperidin-4-yl)piperazines or N-oxides thereof | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7868005-B2 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868005-B2 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7786124-B2 | Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-6403606-B1 | ANTIINFLAMMATORY, ANTIARTHRITIS, A DRUG FOR INHIBITING BONE RESORPTION, IMMUNOSUPPRESSANT | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1124821-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000027842-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2000-05-18 | — | — | WO | disclosed |
| US-6046189-A | ANTI-INFLAMMATORY DRUG, PARTICULARLY, A DRUG FOR PREVENTING OR TREATING ARTHRITIS, A DRUG FOR INHIBITING BONE RESORPTION, IMMUNOSUPPRESSANT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0900223-A1 | THIENOPYRIDINE DERIVATIVES AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040050-A1 | THIENOPYRIDINE DERIVATIVES AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| US-5466687-A | Anticholesterol agents | DR. KARL THOMAE GMBH (DE) | 1995-11-14 | — | — | US | disclosed |
| EP-0596326-B1 | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | THOMAE GMBH DR K (DE) | 1995-08-23 | — | — | EP | disclosed |
| EP-0596326-A1 | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | Dr. Karl Thomae GmbH (DE) | 1994-05-11 | — | — | EP | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157466-A1 | HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, ACKR3, CXCR1 | ALDH1A1 1741/4885HSD17B10 2695/4885HPGD 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.